Beschreibung
HyFect® Transfection Reagent is a low cell toxicity and non-liposome reagent optimized for DNA delivery. It provides effectively, reproducibly, and affordable benefits for scientific research.
-
Übersicht
-
Spezifikationen
-
Anwendung
Cell transfection
Probentyp
Adherent cells | Suspension cells
-
-
Anleitung
-
Versand
The product is shipped with polar packs. Upon receipt, store it immediately at -20°C or lower for long term storage.
Stabilität & Lagerung
This product is stable after storage at:
- -20°C or -80°C for 12 months under sterile conditions from date of receipt.
Avoid repeated freeze/thaw cycles.
-
-
Bild
![Transfection: Cells were transfected with 500 ng of GFP mRNA (left) or mCherry plasmid (right) using two different transfection reagents. The upper row shows results using HyFect® Transfection Reagent (LDG0001RA), with strong fluorescence for mCherry, indicating high transfection efficiency for plasmid. The lower row shows results using HyFect® mRNA-Xpert Transfection Reagent (LDG0003RA), which exhibits significantly stronger GFP (green) fluorescence. Bright-field images are shown alongside fluorescence images to visualize cell morphology.]()
Transfection: Cells were transfected with 500 ng of GFP mRNA (left) or mCherry plasmid (right) using two different transfection reagents. The upper row shows results using HyFect® Transfection Reagent (LDG0001RA), with strong fluorescence for mCherry, indicating high transfection efficiency for plasmid. The lower row shows results using HyFect® mRNA-Xpert Transfection Reagent (LDG0003RA), which exhibits significantly stronger GFP (green) fluorescence. Bright-field images are shown alongside fluorescence images to visualize cell morphology.
1/1 -
Bewertung
Helfen Sie anderen, mehr über dieses Produkt zu erfahren. Nutzen Sie den Link unten, um Ihre Erfahrung zu teilen.
-
Publikation
- Lin YM et al. Biochem Biophys Res Commun. 2022; 630:151-157.
- Hung YH et al. Int J Mol Sci. 2022; 23(5):2608.
- Yang YH et al. Viruses. 2022; 14(5):925.
- Hung YH et al. American journal of cancer research. 2022; 12(2):713-728.
- Cheng YW et al. Journal of Biomedical Science. 2022; 29(1):10.
- Li JN et al. Front Cell Dev Biol. 2021; 9:671244.
- Chang YH et al. PLoS One. 2021; 16(7):e0254011.
- Lin YM et al. Biochem Biophys Res Commun . 2021; 542:59-64.
- Zhu D et al. Exp Ther Med. 2021; 21(1):17.
- Li JN et al. Cancers (Basel). 2021; 13(24):6304.
- Lin LC et al. Int J Med Sci. 2020; 17(14):2214-2224.
- Pinals RL et al. medRxiv. 2020.
- Xue J et al. Oncol Lett. 2020; 19(2):1255-1260.
- Chen PS et al. US patent application. 2019.
- Wu YH et al. Cell Death Dis. 2019; 10(4):322.
- Wang HC et al. Theranostics. 2019; 9(24):7168-7183.
- Wang MY et al. Cancers (Basel). 2019; 11(2):210.
- Lai HH et al. Mol Oncol. 2019; 13(4):928-945.
- Hung WY et al. Cell Physiol Biochem. 2018; 51(1):337-355.
- Lai HH et al. Biochem Biophys Res Commun. 2018; 506(1):87-93.
- Huang YF et al. Clin Cancer Res. 2018; 24(13):3217-3228.
- Chao CH et al. Shock. 2018; 50(1):103-111.
- Lai YC et al. Antiviral Res. 2018; 155:28-38.
- Wu YH et al. Int J Cancer. 2017; 141(11):2305-2317.
- Dai YH et al. Transl Res. 2016; 175:129-143.
- Lai YC et al. Cell Death Dis. 2015; 6(12):e2008.
- Chen HR et al. Biol Open. 2015; 4(2):244-52.
Weitere Publikationen
-
Datenblatt & Dokumente
1/2
Haftungsausschluss：For Research Use or Further Manufacturing Only.
Zuletzt aktualisiert：
